Clinical Trials Sponsored by Eisai Inc.

Total 35665 results

Eisai Inc.

Completed

A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma

Lymphoma, T-Cell, Peripheral

United States
Eisai Inc.

Completed

Exploratory Study, Evaluating the Treatment Effect of Surgery Plus GLIADEL® Wafer in Patients With Metastatic Brain Cancer

Metastatic Brain Cancer

United States
Eisai Inc.

Completed

Evaluating the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

Refractory Partial Seizures

United States, Chile, Brazil, Canada, Mexico, Argentina
Eisai Inc.

Terminated

Trial to Evaluate Safety and Efficacy of Treatment of Physician Choice (TPC) Following First-Line Treatment of Lenvatinib in Subjects With Unresectable Hepatocellular Carcinoma (uHCC)

Carcinoma, Hepatocellular

United States
Eisai Inc.

Completed

A Study to Determine the Metabolism and Elimination of [14C]E2027 in Healthy Male Participants

Dementias With Lewy Bodies

United States
Eisai Inc.

Completed

A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer

Breast Neoplasms

India
Eisai Inc.

Terminated

Open-Label Extension Study of Rufinamide Given as Adjunctive Therapy in Patients With Refractory Partial Seizures

Refractory Partial Onset Seizures

United States
Eisai Inc.

Completed

BLOOM-DM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus

Obesity

United States
Eisai Inc.

Completed

A Multicenter, Double-blind, Randomized, Parallel-group, Pilot Study of 12-week Duration to Assess the Short-term Safety and Tolerability of Lorcaserin Plus Two Doses of Immediate-Release Phentermine-HCl Compared With Lorcaserin Alone in Overweight and Obese Adults

Chronic Weight Management

United States
Eisai Inc.

Completed

Abuse Potential of Single Doses of Lorcaserin in Healthy Recreational Polydrug Users

Healthy | Drug Abuse

Canada
Eisai Inc.

Completed

To Assess the Effect of Lorcaserin Hydrochloride on Energy Metabolism and Food Intake (TULIP)

Obesity

United States
Eisai Inc.

Completed

Phase 1 Study to Determine the Effect of Lenvatinib (E7080) on the Pharmacokinetics of Midazolam in Subjects With Advanced Solid Tumors

Tumors

United States
Eisai Inc.

Completed

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of E2730 in Healthy Participants

Healthy Participants

United States
Eisai Inc.

Completed

Evaluating the Efficacy and Safety of Oral Ranirestat (40 and 80 mg) in Mild to Moderate Diabetic Sensorimotor Polyneuropathy

Mild to Moderate Diabetic Sensorimotor Polyneuropathy

United States
Eisai Inc.

Completed

Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E6742 in Healthy Adult Subjects

Healthy Participants

United States
Eisai Inc.

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2027 in Healthy Subjects

Healthy Subjects

United States
Eisai Inc.

Completed

Phase 0 Study in Healthy, Hepatic and Renal Impaired Subjects to Obtain Plasma for Lenvatinib Protein Binding

Hepatic Impairment; Renal Impairment

United States
Eisai Inc.

Completed

A Global, Postmarketing Observational Safety Study to Evaluate the Safety and Tolerability of Fycompa (Perampanel) as Add-on Therapy in Epilepsy Patients Aged Greater Than or Equal to 12 Years

Epilepsy

Belgium, Israel, United Kingdom, Austria, Sweden, Czechia
Eisai Inc.

Completed

Study to Evaluate Bioavailability of a Single 12 mg Dose of Perampanel for Three Intravenous Infusion Durations Relative to a Single 12 mg Perampanel Oral Tablet in Healthy Subjects

Healthy Participants

United States
Eisai Inc.

Completed

Study of AKR-501 Tablets Taken Orally Once Daily for 28 Days in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP)

Chronic Idiopathic Thrombocytopenic Purpura | Purpura, Thrombocytopenic, Idiopathic

United States
Eisai Inc.

Completed

Efficacy and Safety of Oral E5501 Plus Standard of Care for the Treatment of Thrombocytopenia in Adults With Chronic Immune Thrombocytopenia (Amendment 02)

Immune Thrombocytopenia | Chronic Thrombocytopenia

Poland, Ukraine, Belgium, Bulgaria, South Africa, Netherlands, New Zealand, Singapore, Australia, Slovakia, Czechia
Eisai Inc.

Completed

A Study to Determine the Metabolism and Elimination of 14C-E7080 in Patients With Advanced Solid Tumors or Lymphomas, Who Are Unsuitable For, or Have Failed, Existing Therapies.

Advanced Solid Tumors | Lymphomas

Netherlands
Eisai Inc.

Completed

Evaluation of E2609 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (Study: E2609-A001-101 Amendment 02)

Alzheimer's Disease

United States
Eisai Inc.

Completed

Pharmacokinetics, Efficacy, and Safety of Perampanel Oral Suspension on Seizure Frequency in Pediatric Subjects Maintained on One to Three Stable Antiepileptic Drugs

Central Nervous System

United States
Eisai Inc.

Completed

Comparing the Efficacy, Safety, and Tolerability of Rabeprazole ER 50 mg With Placebo in Subjects With Symptomatic Gastroesophageal Reflux Disease (sGERD)

Symptomatic Gastroesophageal Reflux Disease (sGERD)

United States
Eisai Inc.

Completed

Evaluating E2007 (Perampanel) in Patients With Painful Diabetic Neuropathy (PDN) or Post-Herpetic Neuralgia (PHN)

Neuralgia

United States
Eisai Inc.

Completed

Study of Irofulven in Patients With Hormone-refractory Prostate Cancer

Prostate Cancer

France, United States, Romania, Canada, Peru, Brazil, Russian Federation, Chile, Croatia
Eisai Inc.

Completed

An Open-label, Single Dose Study to Determine the Metabolism and Elimination of [14C]E2609 in Healthy Male Subjects

Metabolism and Elimination

United States
Eisai Inc.

Withdrawn

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of 3 Subcutaneous and 1 Intravenous Dose of E6011 in Subjects With Active Crohn's Disease

Crohn's Disease
Eisai Inc.

Completed

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2609 in Healthy Adult Male Japanese and White Subjects

Healthy Subjects

United States
Eisai Inc.

Completed

A 3-Part, Open-Label, Drug-Drug Interaction Study of Concomitant Administration of E2609 With Itraconazole, Rifampin, Digoxin, or Donepezil

Healthy Subjects

United States
Eisai Inc.

Completed

Evaluation of the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of E2609 in Healthy Subjects

Healthy

United States
Eisai Inc.

Completed

A Single Dose Pharmacokinetic Study of Lorcaserin Hydrochloride in Obese Pediatric Subjects 6 to 11 Years of Age

Obesity

United States
Eisai Inc.

Completed

A Post-marketing Study Evaluating Eslicarbazepine Acetate (ESL) as Adjunctive Treatment in Partial-Onset Seizures (Study E2093-E044-404) (EPOS)

Partial Onset Seizures

France, United Kingdom, Germany, Denmark, Czech Republic, Norway, Sweden, Ireland
Eisai Inc.

Completed

E7080 Food Effect Study in Healthy Subjects

Cancer

United States
Eisai Inc.

Completed

Dosing and Safety Study of E7820 in Patients With a Malignant Solid Tumor or Lymphoma

Neoplasms | Lymphoma, Malignant

United States
Eisai Inc.

Terminated

To Demonstrate Superiority of Decitabine Over Azacitidine in Subjects With Intermediate- or High-risk MDS.

Myelodysplastic Syndromes

United States
Eisai Inc.

Completed

A Randomized, Double-Blind, Placebo-Controlled, Ascending Single Dose Study of E6007 in Healthy Subjects

Inflammatory Bowel Disease

United States
Eisai Inc.

Completed

To Evaluate The Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

Refractory Partial Seizures

United States, France, Germany, Italy, United Kingdom, Belgium, Israel, South Africa, Finland, Russian Federation, Austria, Netherlands, Sweden, India
Eisai Inc.

Terminated

A Study of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations

Parkinson's Disease

Germany
Eisai Inc.

Terminated

Long-Term Safety, Tolerability and Efficacy in Perampanel Treated Parkinson's Disease Patients With Motor Fluctuations

Parkinson's Disease
Eisai Inc.

Completed

A Single-Center, Open-Label, Randomized, 3-Treatment Crossover Bioavailability Study of Single Oral Doses of E5501 Old Tablet Formulation Under Fasted Conditions and a New Tablet Formulation Under Fed and Fasted Conditions in Healthy Subjects

Healthy Subjects

United States
Eisai Inc.

Completed

Compassionate Use of Eribulin for the Treatment of Advanced Breast Cancer Refractory to All Other Marketed Therapies

Breast Cancer

United States
Eisai Inc.

Completed

Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2609 in Healthy Subjects and an Elderly Cohort

Alzheimer's Disease

United States
Eisai Inc.

Completed

A Study of Amolimogene (ZYC101a) in Patients With High Grade Cervical Intraepithelial Lesions of the Uterine Cervix

Uterine Cervical Dysplasia

United States
Eisai Inc.

Completed

A Phase I Open Label Study of E7974 Administered on a Day 1 of 21-Day Cycle In Patients With Advanced Solid Tumors

Cancer, Malignant Tumors

United States
Eisai Inc.

Completed

A Study of Decitabine Given to Adults With Advanced-Stage Myelodysplastic Syndromes

Myelodysplastic Syndrome

United States, Canada
Eisai Inc.

Completed

A Study to Investigate the Potential Pharmacokinetic Interaction of Perampanel With Oral Contraceptives in Healthy Female Subjects

Partial Onset Epilepsy

United Kingdom
Eisai Inc.

Completed

A Study to Demonstrate Bioequivalence Between 6 x 2 mg Tablets of Perampanel and a Single 12 mg Tablet of Perampanel in Healthy Subjects

Partial Onset Epilepsy

United Kingdom
Eisai Inc.

Completed

Evaluation of Efficacy, Safety and Tolerability of Targretin Capsules in Patients With Advanced or Metastatic Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

Canada, United States, United Kingdom, Australia, Israel, Russian Federation, Czech Republic, France, Greece, Hungary, Poland

3

Subscribe